SUNNYVALE, CA, April 28, 2009 – MDS Analytical Technologies, a leading global supplier of drug discovery and life sciences research tools, today announced that its SpectraMax® L microplate luminometers have received Dual-Luciferase Reporter Assay (DLReady or DLR) certification from Promega Corporation, a leader in providing innovative solutions and technical support to the life sciences industry.

This certification confirms that SpectraMax® L microplate luminometers meet Promega’s performance criteria for the Dual-Luciferase Reporter Assay maximizing the success of researchers in their work.

“DLReady certification by Promega provides our mutual customers with greater assurance of excellent performance for this highly sensitive, accurate, and rapid assay on the SpectraMax® L microplate luminometer,” said Andy Boorn, President of MDS Analytical Technologies. “DLR certification extends to the entire family of SpectraMax® L readers, including our multiple-detector-based luminometer released earlier this year.”

The Dual-Luciferase Reporter Assay is widely used to study gene transcription and regulation. This dual-reporter assay enables normalization of the activity of an experimental reporter to the activity of an internal control, minimizing experimental variability caused by differences in cell viability or transfection efficiency. The activities of two enzymes – firefly luciferase and Renilla luciferase – are measured sequentially from a single sample. DLR-certified luminometers undergo an extensive validation process to help users obtain the best possible performance with the Dual-Luciferase Reporter Assay.

“Promega has tested and certified that the SpectraMax® L microplate luminometer meets our criteria for performance with the Dual-Luciferase Reporter Assay,” said Kevin Kopish, Global Product Manager for Cellular Analysis at Promega Corporation. “The DLReady program ensures that customers can have confidence in their scientific results and not worry about reagent or instrument performance.”

To download more information, please visit www.moleculardevices.com/pages/instruments/spectramax_l.html. Alternatively, customers can call the Customer Service department at (408) 747-1700 to speak to a sales representative.

About SpectraMax® L Microplate Luminometer

MDS Analytical Technologies, which acquired Molecular Devices Corporation in 2007, is a leading supplier of microplate reader systems to academic, pharmaceutical, and biotechnology research groups worldwide. The SpectraMax® L microplate luminometers offer the sensitivity, reliability, flexibility, upgradability, automation options, and validation tools required by today’s leading laboratories. The systems are ideal for measuring flash and glow assays, including dual luciferase reporter gene, G protein-coupled receptor (GPCR) via aequorin, bioluminescence resonance energy transfer (BRET), and acridinium ester flash assays, in both 96- and 384-well plates. The SpectraMax® L system can be upgraded to multi-channel configurations for a 6-fold increase in throughput for medium throughput and secondary screening laboratories. Industry-leading SoftMax® Pro software eliminates the need to export data to spreadsheet programs, and manages instrument control and results generation in a GxP environment. SoftMax® Pro GxP software and its software validation package provide comprehensive documentation and extensive data sets in CD-ROM format to meet FDA 21 CFR Part 11 and GxP compliance requirements. To learn more, go to https://www.moleculardevices.com/pages/instruments/readers_main.html.

About MDS Analytical Technologies

MDS Analytical Technologies, a business unit of MDS Inc., is focused on the research, design, manufacture and marketing of state-of-the-art tools for mass-spectrometry, drug discovery and bioresearch. MDS Analytical Technologies’ products are designed to help accelerate the complex process of discovering and developing new drug compounds, and are sold to research scientists around the world. The mass-spectrometer product lines are also sold globally through joint ventures with two of the world’s leading analytical instrumentation and life-sciences companies, Life Technologies Corporation and PerkinElmer, Inc. Find out more at www.mdssciex.com or www.moleculardevices.com.

About MDS Inc.

MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life-sciences company that provides market-leading products and services that our customers need for the development of drugs and diagnosis and treatment of disease. We are a leading global provider of pharmaceutical contract research, medical isotopes for molecular imaging, radiotherapeutics, and analytical instruments. MDS, Inc. has more than 5,000 highly skilled people in 29 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.